Innovative, world-leading treatment of diseases
related to the Complement System

Innovative, world-leading treatment of diseases
related to the Complement System

Complement Therapeutics is a company focused on developing novel solutions to modulate Complement System disorders that give rise to both common and rare disease.

The company is committed to pursuing clinical success through innovative thinking and research and the translation of these into effective treatments.

The Complement System

The Complement System is an integral part of the body’s immune system, so called because it enhances (complements) the functional ability of antibodies and phagocytic cells. It plays a key role in protecting the body against invasion of harmful bacteria and contributes to the removal of the body’s own damaged and altered cells.

Activation of the Complement System is a very precisely controlled process that is managed by a series of regulatory proteins.

Deficiencies in the Complement System’s proteins can lead to microbial infections and diseases such as rheumatoid arthritis.

Over-activation of the Complement System can lead to chronic diseases such as age-related macular degeneration, renal and neurological disease.

Complement Therapeutics is dedicated to developing therapeutics that normalise Complement System function to treat a variety of diseases.

Diseases related to disorders in the Complement System

  • Macular degeneration
  • Sepsis
  • Trauma
  • Haemodialysis
  • C3G
  • PNH
  • aHUS
  • TMA
  • Stroke/Infarction
  • Transplantation
  • Periodontitis
  • SLE
  • Alzheimer’s disease

Therapeutic options

An increasing number of clinical conditions are being linked to the Complement System.

These have spurred interest in therapeutic approaches to modulate complement system activity.

Complement Therapeutics is deeply involved with these regulatory and modulatory processes via the development of different therapeutic modalities and combining this with its unique complementome platform capable of measuring levels of circulating complement proteins to target the Complement pathway and treat disease such as Geographic Atrophy in age-related macular degeneration.

Core Technology Facility
46 Grafton Street
M13 9NT
United Kingdom

Created by HTP Digital